OPKO Health Q2 2026: Narrowed Loss, Pipeline Momentum, and Full-Year Guidance
OPK sits 47% above its 52-week low of $0.977.
Summary
OPKO Health posted Q2 2026 revenue of $163.5 million and a net loss of just $8.4 million, a dramatic improvement from the prior year. The company also issued full-year revenue guidance of $560–$585 million and highlighted progress across its clinical pipeline, including three new Phase 1 trials.
Key Events · Earnings and Guidance · OPK
-
Q2 Loss Narrows Sharply
Net loss improved to $8.4 million ($0.01/share) from $148.4 million ($0.19/share) in Q2 2025, driven by a $29.4 million IP revenue boost from the Nicoya amendment and an $18.1 million Labcorp earnout.
-
Full-Year Revenue Guidance Issued
OPKO guided for 2026 total revenue of $560–$585 million, with services revenue of $296–$306 million, product revenue of $164–$174 million, and IP/other revenue of $100–$105 million.
-
Pipeline Advances with Three Phase 1 Starts
MDX2003 (B-cell lymphoma), MDX2301 (COVID-19 prevention, BARDA-funded), and OPK-88006 (MASH) all initiated Phase 1 trials, with initial data expected in late 2026 or early 2027.
-
Nicoya Deal Amended for Equity Stake
OPKO received a 15% equity stake in Nicoya in exchange for revised royalties, while retaining up to $115 million in milestones; the deal also recognized $29.4 million in Q2 IP revenue.
Analysis · OPK · Life Sciences
A significantly improved second quarter saw OPKO Health's net loss shrink to $8.4 million from $148.4 million a year ago, fueled by higher intellectual property revenue and an $18.1 million earnout from the Labcorp asset sale. Full-year 2026 revenue guidance of $560–$585 million underscores confidence in the commercial trajectory. Meanwhile, multiple clinical programs advanced—Phase 1 initiations for MDX2003, MDX2301, and OPK-88006—and the amended Nicoya deal delivered a 15% equity stake while preserving up to $115 million in milestones. With $314.4 million in cash and an active share buyback, the company is balancing pipeline investment with shareholder returns.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPK was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $936.3M. The 52-week trading range was $0.98 to $1.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.